

RECEIVED

JECHCENTER 4607770

SUBSTITUTE FORM PTO-1449 (MODIFIED) Attorney Docket No. U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Serial No. 09/496,231 Hubbell et al. Applicant INFORMATION DISCLOSURE Filing Date February 1, 2000 STATEMENT BY APPLICANT (Use several sheets if necessary) Group (37 C.F.R. § 1.98(b)) **IDS Filed** December 8, 2003

			U.S. PATENTS			
Examiner's Initials	Patent Number	issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
(M)	4,618,400	10/21/86	Wood			
	5,801,033	9/1/98	Hubbell et al.			
	5,858,746	1/12/99	Hubbell et al.			
	5,932,462	8/3/1999	Harris et al.			
	2003-0044468	3/6/2003	Cellesi et al.			
	2003-0059906	3/27/2003	Hubbell et al.			
U ₁	FORI	EIGN PATENT (OR PUBLISHED FOREIGN PATEN	T APPLICATIO	ON	
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
(18)	GB 1,348,045	03/13/74	United Kingdom			
						
1	/ OTHER DOCI	JMENTS (INCL	UDING AUTHOR, TITLE, DATE, PL	ACE OF PUB	LICATION)	
1 1			orphyrins as Novel Initiators for the l 3887-3892 (1990).	Living and Imn	nortal Polyme	rizations of
7070	Blume et al., "Spe the Ends of the P Biophys. Acta., 1	olymeric Chains	with Poly(ethylene glycol)-modified a Combines Effective Target Binding 193).	Liposomes: Co with Long Cir	oupling of Hor culation Time	ming Devices to es," Biochim.
			hitecture and Composition on the A " Macromol. Chem. Rapid Commun			y(oxyalkylene)
	Discher et al., "Po (1999).	olymersomes: T	ough Vesicles Made from Diblock C	opolymers," S	cience, 284:1	143-1146
	Gabizon, "Targeti Liposomes: In Vit	ng Folate Rece ro Studies,* Bio	ptor with Folate Linked to Extremitie conjugate Chem., 10:289-298 (1999	s of Poly(ethyl	ene glycol)-G	rafted
17			ıman Bladder Cancer with Adenovir Research, 6:4422-4431 (2000).	us-mediated A	Intisense Bas	ic Fibroblast
,	Lasic et al., ed. S	ealth Liposome	s, Chapters 2, 4, and 9, CRC Press	: Boca Raton,	FL, (1995).	
	Mortensen, "Block Colloid, Polym, Sc	Copolymer in . ci., 93:72-75 (19	Aqueous Solution: Micelle Formation 93).	n and Hard-sp	here Crystalli	zation," Prog.
XAMINER	[AXI	us	DATE CONSIDER	ED	117	
XAMINER: In	itial citation conside ext communication	red. Draw line to applicant.	hrough citation if not in conformance	e and not cons	sidered./Inclu	ide copy of this

Sheet 2 of 2

EN S TRADES 50154/002002 Attorney Docket No. SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 09/496,231 Serial No. Hubbell et al. Applicant INFORMATION DISCLOSURE Filing Date February 1, 2000 STATEMENT BY APPLICANT (Use several sheets if necessary) 1651 Group IDS Filed December 8, 2003 (37 C.F.R. § 1.98(b))

		Torchilin et al., "Poly(ethylene glycol) on the Liposome Surface: on the Mechanism of Polymer-coated Liposome Longevity," Biochim. Biophys. Acta, 1195:11-20 (1994).
7		Watanabe et al., "First Example of Photoinduced Copolymerizability Enhancement. Copolymerization of Epoxide and Episulfide Initiated with Zinc N-substituted Porphyrin under Visible Light Irradiation," Macromolecules, 24:3970-3972 (1991).
		Won, "Giant Wormlike Rubber Micelles," Science, 283:960-963, (1999).
	1	Yu et al., "Bilayer Morphologies of Self-assembled Crew-cut Aggregates of Amphiphilic PS-b-PEO Diblock Copolymers in Solution," Macromolecules, 31:3509-3518, (1998).
	1	Zalipsky et al., "Peptide Attachment to Extremities of Liposomal Surface Grafted PEG Chains: Preparation of the Long-circulating Form of Laminin Pentapeptide, YIGSR," Bioconjugate Chem., 6:705-708 (1995).
n		Zalipsky, "Long-circulating, Polyethylene Glycol-grafted Immunoliposomes," J. Controlled Release, 39:153-161 (1996).

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

OIPE	
MAY 5.0 STORE	2 3014
FRAUGUS TRAUGUS	STITU

MODIFIED)

(37 C.F.R. § 1.98(b))

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50154/002002

Serial No.

09/496,231

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) Applicant
Filing Date

February 1, 2000

Jeffrey A. Hubbell et al.

Group

1651

IDS Filed

May 18, 2005

			L			
		U.	S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
In	5,428,014 A	6/27/1995	Labroo et al.			
	5,958,874 A	9/28/1999	Clark et al.			
	6,136,564 A	10/24/2000	Kopetzki et al.			
				<u> </u>		
	FOREIGI	N PATENT OR I	PUBLISHED FOREIGN PATENT A	PPLICATION	ON	
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
M	WO 03/040235 A1	5/15/2003	WIPO			
	/					
(1/	OTHER DOCUME	NTS (INCLUDI	NG AUTHOR, TITLE, DATE, PLAC	E OF PUB	LICATION)	
UNV	Luginbuehl et al., "Lo (2004).	calized Delivery	of Growth Factors for Bone Repai	r," Eur. J. P	harm. Biopha	arm. 58:197-208
	_	•				

		$oxed{oxed}$				
EXAMINER A 2/1	DATE CONSIDERED	[8]	07			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

014	4	- 4	
Sheet	- 1	of	- 1

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50154/002002
(MOROTOPE)	PATENT AND TRADEMARK OFFICE	Serial No.	09/496,231
(A)	0.4 B1001 001 IDE	Applicant	Jeffrey A. Hubbell et al.
STATEMEN	ON DISCLOSURE T BY APPLICANT sheets if necessary)	Filing Date	Februrary 1, 2000
(37 C.F.R. § 1.98(b))	sneets ii netessary)	Group	1651
(37 C.F.R. § 1.98(b))		IDS Filed	November 17, 2004

			U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
(M)	5702717	12/30/1997	Han et al.			
					<u> </u>	
	FOR	FIGN PATENT	OR PUBLISHED FOREIGN PATEN	T APPLICATION) DN	
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
M	WO 00/44808	08/03/2000	WIPO			
	WO 01/02017	01/11/2001	WIPO			
	WO 98/32466	07/30/1998	WIPO			
	OTHER DOC	UMENTS (INCL	UDING AUTHOR, TITLE, DATE, PL	ACE OF PUB	LICATION)	
	Greenwald et al ' Activity" Bioorgai	*Camptothecin-2 nic & Medicinal (20-PEG Ester Transport Forms: the Chemistry 1998, 6:551-562.	Effect of Spac	er Groups on	Antitumor
1/	Kopecek et al. "C N.Y. Acad. Sci. 1		se of Drug Model from N-(2-Hydrox) 4.	ypropyl)-metha	crylamide Co	polymers" Ann.
	Pendri et al. "Ant Prodrug" Anti-ca	itumor Activity oncer Drug Desig	f Paclitaxel-2'-glycinate Conjugated n 1998, 13:387-395.	to Poly(ethyle	ne glycol): a \	Vater-soluble
\ <i>[</i>						

EXAMINER	(Ani Chong	DATE CONSIDERED /	18/07			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this						

form with the next communication to applicant.

HECEIVED

FGP 3 8 2244

JECH CENTER 1600/2900

A RECEIVE 50154/002002 Attorney Docket No. SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 09/496,231 Serial No. Hubbell et al.. Applicant INFORMATION DISCLOSURE February 1, 2000 Filing Date STATEMENT BY APPLICANT (Use several sheets if necessary) 1651 Group January 26, 2004 IDS Filed (37 C.F.R. § 1.98(b))

Examiner's Initials	Patent Number	Issue Date	, F	Patentee	 Class	Subclass	Filing Date (If Appropriate)
In (5,529,914	6/25/96	Hubbell et al.				
1/	5,575,815	11/19/96	Slepian et al.				
	·						
	;						
						• .	
	 						
•							
·		<u> </u>					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Clas	s Subclass	Translation (Yes/No)	
100	WO 00/09087	24.2.00	WIPO		•	·	
- U -							

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE; DATE, PLACE OF PUBLICATION)							

·					
EXAMINER	CANKEDLO	DATE CONSIDERED	- 1//	ا/وا	· —
EXAMINER: Init	tial citation considered. Draw line through cita	tion if not in conformance and n	ot consi	dered	I. Include copy of this